Title: The Role of Delafloxacin in Patients with Community-Acquired Bacterial Pneumonia in the Outpatient Setting: A Budget Impact Analysis

Journal: Clinical Drug Investigation

Thomas P Lodise\textsuperscript{1} PharmD, PhD, Glenn S Tillotson\textsuperscript{2} PhD, FIDSA, FCCP, Andrew Spargo\textsuperscript{3} PharmD, MBA, Duygu Bozkaya\textsuperscript{3}, MSc, MBA, Janelle Massey\textsuperscript{4} PharmD, MBA.

1. Albany College of Pharmacy and Health Sciences, Albany, NY, USA
2. GST Micro LLC, Henrico, VA, USA
3. Xcenda, Tampa, FL, USA
4. Melinta Therapeutics, Inc. New Haven, CT, USA
## Supplemental Table 1. Budget Impact Model Comparators

| Comparators                                      | Dosing                  | Treatment Duration | Source                      |
|--------------------------------------------------|-------------------------|--------------------|-----------------------------|
| Delafloxacin 450 mg tablets                      | BID                     | 5 days             | BAXDELA® [package insert]   |
| Omadacycline 100 mg vial and 300 mg tablets      | IV infusion: 200 mg IV over 60 minutes on day 1 Oral tablets: 300 mg QD | 7 days             | NUZYRA® [package insert]    |
| Lefamulin 600 mg tablets                         | BID                     | 5 days             | XENLETA™ [package insert]   |
| Levofloxacin 750 mg tablets                      | QD                      | 5 days             | LEVAQUIN® [package insert]  |
| Moxifloxacin hydrochloride 400 mg tablets        | QD                      | 7 days             | AVELOX® [package insert]    |
| Doxycycline hyclate 100 mg tablets               | BID                     | 5 days             | Mandell 2007                |
| Amoxicillin and clavulanate potassium 1000 mg-62.5 mg extended release tablets | 2000 mg–125 mg BID      | 5 days             | Mandell 2007                |
| Azithromycin 250 mg tablets                      | 500 mg on day 1; 250 mg on days 2–5 | 5 days             | ZITHROMAX® [package insert] |
| Amoxicillin 500 mg capsules and azithromycin 250 mg tablets | Amoxicillin: 1 g TID Azithromycin: 500 mg on day 1; 250 mg on days 2–5 | 5 days             | ZITHROMAX® [package insert] |

Key: BID – 2 times daily; IV – intravenous; QD – once daily; TID – 3 times daily.

All trademarks are the property of their respective owners.
**Supplemental table 2. Market Shares Used for the Base-case Assessment of Budget Impact**

| Comparator                                                   | Current Environment, % | New Environment, % |
|--------------------------------------------------------------|------------------------|--------------------|
| Delafloxacin                                                 | 0.0                    | 1.0                |
| Omadacycline                                                 | 0.3                    | 0.3                |
| Lefamulin                                                    | 0.2                    | 0.2                |
| Levofloxacin                                                 | 38.0                   | 38.0               |
| Moxifloxacin                                                 | 5.0                    | 4.0                |
| Doxycycline hyclate                                          | 6.0                    | 6.0                |
| Amoxicillin and clavulanate potassium extended release       | 7.0                    | 7.0                |
| Azithromycin                                                 | 37.5                   | 37.5               |
| Amoxicillin                                                  | 6.0                    | 6.0                |

*Market shares in the current and new environments were based on data on file.*
**Supplemental Table 3. Drug Costs**

| Product                                                      | WAC per Dose (Base-Case) | AWP per Dose (Alternative) | Source                                                   |
|--------------------------------------------------------------|---------------------------|----------------------------|----------------------------------------------------------|
| Delafloxacin                                                 | $74.42                    | $89.30                     | NDC 70842-0101-01 (RED BOOK 2019)                        |
| Omadacycline (vial)                                          | $345.00                   | $414.00                    | NDC 71715-0001-02 (RED BOOK 2019)                        |
| Omadacycline (tablet)                                        | $197.50                   | $37.00                     | NDC 71715-0002-23 (RED BOOK 2019)                        |
| Lefamulin                                                    | $137.50                   | $165.00                    | NDC 72000-0110-30 (RED BOOK 2019)                        |
| Levofloxacin                                                 | $0.44                     | $24.61                     | NDC 00904-6353-61 (RED BOOK 2019)                        |
| Moxifloxacin                                                 | $2.94                     | $27.23                     | NDC 65862-0603-30 (RED BOOK 2019)                        |
| Doxycycline hydrochlorate                                    | $0.70                     | $0.84                      | NDC 23155-0376-25 (RED BOOK 2019)                        |
| Amoxicillin and clavulanate potassium extended release       | $6.70                     | $8.04                      | NDC 43598-0020-28 (RED BOOK 2019)                        |
| Azithromycin                                                 | $0.88                     | $7.78                      | NDC 69452-0171-13 (RED BOOK 2019)                        |
| Amoxicillin                                                  | $0.08                     | $0.44                      | NDC 00143-9939-01 (RED BOOK 2019)                        |

Key: AWP – average wholesale price; NDC – National Drug Code; WAC – wholesale acquisition cost.
| Outcome                  | Cost    | Source                                      |
|-------------------------|---------|---------------------------------------------|
| Treatment response      | $60.03  | Lodise 2017                                 |
| Treatment non-response  |         |                                             |
| Retreatment$^a$         | $678.07 | Data on File; Melinta Therapeutics          |
| ER visit                | $4,365.22 | Lodise 2017                                 |
| Hospitalization         | $29,665.06 | Lodise 2017                                 |

$^a$ Retreatment represents a composite of a refill of the previous antibiotic agent or a new prescription for a new antibiotic agent.

Key: ER – emergency room.
Supplemental Figure 1  One-way Sensitivity Analysis Tornado Chart for the Base-Case Assessment of Budget Impact

### Sensitivity Analysis Results: Base-Case

| Category                                                                 | High Input | Low Input |
|------------------------------------------------------------------------|------------|-----------|
| Treatment duration, delafloxacin                                       | $52,275    | $65,699   |
| Cost per dose (WAC, day 1), delafloxacin                               | $52,276    | $65,697   |
| Plan Size (members)                                                    | $53,088    | $64,885   |
| Number of doses on remaining days, delafloxacin                        | $53,617    | $64,356   |
| Annual incidence of CABP, 18-64 years                                  | $55,589    | $62,385   |
| % of plan aged 18-64 years, private plan                               | $55,757    | $62,216   |
| % of members in private plan                                           | $56,034    | $61,939   |
| % of patients without COPD/asthma not responding due to lack of efficacy, delafloxacin | $56,373    | $61,600   |
| % of patients without COPD/asthma not responding due to lack of efficacy, moxifloxacin | $56,373    | $61,600   |
| Annual incidence of CABP, ≥ 65 years                                   | $56,486    | $61,487   |

Key: CABP – community-acquired bacterial pneumonia; COPD – chronic obstructive pulmonary disease; WAC – wholesale acquisition cost.